doi: 10.1161/hs0202.102599
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2002;33:493.)
© 2002 American Heart Association, Inc.
Original Contributions |
ATLANTIS Trial
Results for Patients Treated Within 3 Hours of Stroke Onset
From Stanford University School of Medicine, Stanford, Calif (G.W.A., S.A.H.); Oregon Health Sciences University, Portland (W.M.C.); Marshfield Clinic, Marshfield, Wis (K.P.M.).
Correspondence to Gregory W. Albers, MD, Director, Stanford Stroke Center, 701 Welch Rd, Bldg B, Suite 325, Palo Alto, CA 94304.
Background and Purpose— Only a single study has demonstrated beneficial effects of intravenous tissue plasminogen activator (tPA) in stroke patients.
Methods— We evaluated the clinical outcomes of the 61 patients enrolled in the Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study who were randomized to receive intravenous tPA or placebo within 3 hours of symptom onset.
Results— Despite a significant increase in the rate of symptomatic intracranial hemorrhage, tPA-treated patients were more likely to have a very favorable outcome (score of 
1) on the National Institutes of Health Stroke Scale at 90 days (P=0.01).
Conclusions— These data support current recommendations to administer intravenous tPA to eligible ischemic stroke patients who can be treated within 3 hours of symptom onset.
Editorial Comment
Results for Patients Treated Within 3 Hours of Stroke Onset
This article has been cited by other articles:
 |
|
 |
|
  S. Chew, S. A Kausar, and S. Sturman Thrombolysis in acute ischaemic stroke pathway J Integr Care Pathw, January 1, 2008; 12(1): 10 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Chung, R R Camejo, and D Barnett Alteplase for the treatment of acute ischaemic stroke: NICE technology appraisal guidance Heart, December 1, 2007; 93(12): 1616 - 1618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Dirks, L. W Niessen, P. J Koudstaal, C. L Franke, R. J van Oostenbrugge, D. W J Dippel, and the members of the Delphi panel on indications and Intravenous thrombolysis in acute ischaemic stroke: from trial exclusion criteria to clinical contraindications. An international Delphi study J. Neurol. Neurosurg. Psychiatry, July 1, 2007; 78(7): 685 - 689. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G TAN and T GODDARD Neuroimaging applications of multislice CT perfusion Imaging, June 1, 2007; 19(2): 142 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Engelter, L. H. Bonati, and P. A. Lyrer Intravenous thrombolysis in stroke patients of >=80 versus <80 years of age--a systematic review across cohort studies. Age Ageing, November 1, 2006; 35(6): 572 - 580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Weller, H.-J. Wittsack, M. Siebler, V. Homberg, and R. J. Seitz Motor recovery as assessed with isometric finger movements and perfusion magnetic resonance imaging after acute ischemic stroke. Neurorehabil Neural Repair, September 1, 2006; 20(3): 390 - 397. [Abstract] [PDF]
|
|
|
|
 |
|
 H.-H. Hu, M. M.-H. Teng, L.-C. Hsu, W.-J. Wong, L.-M. Wang, Y.-O. Luk, C.-M. Chern, B.-W. Soong, and W.-Y. Sheng A Pilot Study of a New Thrombolytic Agent for Acute Ischemic Stroke in Taiwan Within A Five-Hour Window Stroke, March 1, 2006; 37(3): 918 - 919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. T. Engelter, M. Reichhart, L. Sekoranja, D. Georgiadis, A. Baumann, B. Weder, F. Muller, R. Luthy, M. Arnold, P. Michel, et al. Thrombolysis in stroke patients aged 80 years and older: Swiss survey of IV thrombolysis Neurology, December 13, 2005; 65(11): 1795 - 1798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J M U-King-Im, R A Trivedi, M J Graves, K Harkness, H Eales, I Joubert, B Koo, N Antoun, E A Warburton, J H Gillard, et al. Utility of an ultrafast magnetic resonance imaging protocol in recent and semi-recent strokes J. Neurol. Neurosurg. Psychiatry, July 1, 2005; 76(7): 1002 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. W. Wojner-Alexandrov, A. V. Alexandrov, D. Rodriguez, D. Persse, and J. C. Grotta Houston Paramedic and Emergency Stroke Treatment and Outcomes Study (HoPSTO) Stroke, July 1, 2005; 36(7): 1512 - 1518. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hill, A. M. Buchan, and for The Canadian Alteplase for Stroke Effectivenes Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study Can. Med. Assoc. J., May 10, 2005; 172(10): 1307 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Culp, T. R. Porter, J. Lowery, F. Xie, P. K. Roberson, and L. Marky Intracranial Clot Lysis With Intravenous Microbubbles and Transcranial Ultrasound in Swine Stroke, October 1, 2004; 35(10): 2407 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. W. Albers, P. Amarenco, J. D. Easton, R. L. Sacco, and P. Teal Antithrombotic and Thrombolytic Therapy for Ischemic Stroke: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 483S - 512S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. T. Higashida and A. J. Furlan Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke Stroke, August 1, 2003; 34 (8): e109 - e137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Broderick and W. Hacke Treatment of Acute Ischemic Stroke: Part I: Recanalization Strategies Circulation, September 17, 2002; 106(12): 1563 - 1569. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lenzer, C. Warlow, J. L Saver, C. S Kidwell, and S. Starkman Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign * Commentary: Who pays the guideline writers? * Commentary: Thrombolysis in stroke: it works! BMJ, March 23, 2002; 324(7339): 723 - 729. [Full Text] [PDF]
|
|